

JAN 26 2001

**510(k) Summary – Elecsys® FSH CalSet II**

---

<b>Introduction</b>	According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.
---------------------	--

---

<b>Submitter name, address, contact</b>	<p>Roche Diagnostics Corporation 9115 Hague Rd Indianapolis IN 46250 (317) 576-3544</p> <p>Contact person: Kay A. Taylor</p> <p>Date prepared: October 31, 2000</p>
---	---

---

<b>Predicate device</b>	Roche Diagnostics Elecsys® FSH CalSet II is substantially equivalent to other devices legally marketed in the United States. We claim equivalence to the currently marketed Roche Diagnostics Elecsys® FSH CalSet.
-----------------------------	--

---

<b>Device description</b>	Roche Diagnostics Elecsys® FSH CalSet II consists of lyophilized equine serum matrix with added human FSH in two concentration ranges.
-------------------------------	--

---

<b>Intended use / Indication for use</b>	Roche Diagnostics Elecsys® FSH CalSet II is intended for the calibration of the quantitative FSH assay on the Elecsys® immunoassay analyzer systems.
--	--

---

<b>Substantial equivalence</b>	Elecsys® FSH CalSet II is equivalent to other devices legally marketed in the United States. We claim equivalence to the currently marketed Roche Diagnostics Elecsys® FSH CalSet cleared under document K964693.
------------------------------------	---

---

## 510(k) Summary – Elecsys® FSH CalSet II, continued

### Substantial equivalence – similarities

The following table compares Elecsys® FSH CalSet II, with the predicate device Elecsys® FSH CalSet.

Characteristic	Elecsys® FSH CalSet II	Elecsys® FSH CalSet
Intended Use	For the calibration of the quantitative FSH assay on the Elecsys immunoassay systems.	For the calibration of the quantitative FSH assay on the Elecsys immunoassay systems.
Levels	Two levels	Two levels

### Substantial equivalence -- differences –

Characteristic	Elecsys® FSH CalSet II	Elecsys® FSH CalSet
Format	Lyophilized	Liquid
Matrix	Equine serum matrix with added human FSH	Equine serum matrix with added human FSH
Stability	<ul style="list-style-type: none"> <li>• Unopened Stable at 2-8° C until expiration date</li> <li>• Reconstituted: <ul style="list-style-type: none"> <li>✓ -20°C - 3 months (only freeze once)</li> <li>✓ On analyzer – 3 hours (only use once)</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Unopened Stable at 2-8° C until expiration date</li> <li>• Reconstituted: <ul style="list-style-type: none"> <li>✓ 2-8°C – 12 weeks</li> <li>✓ On analyzer – 5 hours</li> </ul> </li> </ul>



JAN 26 2001

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Ms. Kay A. Taylor  
Regulatory Affairs Consultant, Laboratory Systems  
Roche Diagnostics Corporation  
9115 Hague Road  
PO Box 50457  
Indianapolis, Indiana 46250-0457

Re: K003409  
Trade Name: Elecsys® FSH CalSet II  
Regulatory Class: II  
Product Code: JIT  
Dated: December 19, 2000  
Received: December 21, 2000

Dear Ms. Taylor:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act and the following limitations:

1. The device cannot be marketed or promoted for use on instrumentation that has not gone through the premarket notification process.

The general controls of the Act include requirements for annual registration, listing of devices, good manufacturing practices, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 – Ms. Kay A. Taylor

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

  
Steven I. Gutman, M.D., M.B.A.

Director

Division of Clinical Laboratory Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

## INDICATIONS FOR USE STATEMENT

510(k) Number (if known): N/A K003409

Device Name: Elecsys® FSH CalSet II

Indications For Use:

For the calibration of the quantitative FSH assay on the Elecsys® Immunoassay analyzer systems.

Joan Cooper  
(Division Signature)  
Division K 003409  
510(k) Number K 003409

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)  
Prescription Use ☒ OR Over-The-Counter Use ☐  
(Per 21 CFR 801.109)

(Optional Format 1-2-

96)